About Oragenics Our corporate strategy is aimed at adding value to novel technologies and products sourced from innovative research at the University of Florida and other academic centers. Our aim is to develop products through human proof-of-concept (Phase I or II of the FDA's regulatory process) prior to partnering with major pharmaceutical, biotechnology or healthcare product firms for advanced clinical development and commercialization. We are currently developing the following products, each of which addresses potential market opportunities: Replacement Therapy Mutacin 1140 "Probiotic" technology IVIAT / CMAT Target Identification... [ READ MORE ]

About Oragenics | Product Portfolio | Press Room | Investor Relations | Contact Us | Copyright Oragenics | Design by